{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:30:44Z","timestamp":1789075844605,"version":"build-2803163510"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2003,6,5]],"date-time":"2003-06-05T00:00:00Z","timestamp":1054771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2003,9,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A dipeptide, L\u2010glutamyl L\u2010tryptophan (L\u2010glu\u2010L\u2010trp), was identified in a screen for immunomodulators in the soluble fraction of the thymus. L\u2010glu\u2010L\u2010trp inhibits tumor growth in mice without showing direct cellular toxicity in a variety of human tumor cell lines. L\u2010glu\u2010L\u2010trp antitumor activity <jats:italic>in vivo<\/jats:italic> requires the presence of natural killer (NK) cells. Defective trafficking of cytoplasmic granules caused by the <jats:italic>Lyst<\/jats:italic> mutation also resulted in loss of antitumor activity of the dipeptide. The effect of L\u2010glu\u2010L\u2010trp on tumor growth in mice with targeted gene mutations demonstrated the absolute requirement for perforin for antitumor activity. The requirement of 2 major modulators of NK cell activity, gamma interferon (IFN\u03b3) and interleukin (IL)\u201012, were also tested. L\u2010glu\u2010L\u2010trp had full antitumor activity in IFN\u03b3 knockout mice, but had significantly diminished activity in IL\u201012 knockout mice. These data show that L\u2010glu\u2010L\u2010trp antitumor activity in mice is dependent on cytolytic cell activity of NK or NKT cells. L\u2010glu\u2010L\u2010trp <jats:italic>in vivo<\/jats:italic> regulates NK cell function independent of IFN\u03b3 but partly dependent on IL\u201012. \u00a9 2003 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.11253","type":"journal-article","created":{"date-parts":[[2003,7,2]],"date-time":"2003-07-02T10:03:23Z","timestamp":1057140203000},"page":"528-533","source":"Crossref","is-referenced-by-count":13,"title":["Natural killer cell cytolytic activity is necessary for <i>in vivo<\/i> antitumor activity of the dipeptide L\u2010glutamyl\u2010L\u2010tryptophan"],"prefix":"10.1002","volume":"106","author":[{"given":"D. Lynne","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SuTao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjai","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Masood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parkash S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,6,5]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200007063430107"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(97)80169-0"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(95)80122-7"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.12.040194.003511"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00198-6"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.17.1.189"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9098(199806)68:2<122::AID-JSO10>3.0.CO;2-4"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0192-0561(97)00058-1"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010042008969"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.4.1245"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.13.974"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900201)65:3<492::AID-CNCR2820650320>3.0.CO;2-C"},{"key":"e_1_2_5_15_2","first-page":"2693","article-title":"Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma","volume":"7","author":"Masood R","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_16_2","unstructured":"MorozovVG KhavinsonVK. Thymus\u2010gland preparation and method for producing same. United States Patent No. 5 070 076."},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/382262a0"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/369031a0"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.11.6658"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.127.5.1754"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.127.1.34"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.149.2.403"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/83416"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1006\/mgme.1999.2927"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.154.11.6122"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.136.11.4134"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.12.6488"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.9.1611"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.170.3.827"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.3.1662"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.2.583"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.4.1847"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.11253","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.11253","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.11253","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.11253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T14:31:22Z","timestamp":1692628282000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.11253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,5]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,9,10]]}},"alternative-id":["10.1002\/ijc.11253"],"URL":"https:\/\/doi.org\/10.1002\/ijc.11253","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,5]]}}}